What Prostamax is
Prostamax is the tetrapeptide KEDP, marketed as a prostate “bioregulator.” It has no FDA-approved product, prostate indication, or dose.
Evidence does not establish a prostate treatment
One study used a rat model of chronic aseptic prostatitis.[1] Other reports exposed human lymphocytes to KEDP and measured chromatin changes.[2] A patent's clinical examples are not peer-reviewed trials. No reliable controlled human evidence establishes relief of urinary symptoms, prostatitis treatment, smaller prostate volume, cancer prevention, or improved sexual function.
Safety and diagnostic delay
Adverse events, interactions, pregnancy exposure, fertility effects, cancer biology, and long-term safety are undefined. Prostate and urinary symptoms need appropriate evaluation because infection, obstruction, pelvic-pain disorders, and cancer require different care.
Regulatory status
Prostamax is unapproved in the United States. Compounded drugs are not FDA-approved or premarket-verified for safety, effectiveness, or quality.[3] Teloryx publishes no dose or preparation protocol.